Rehmannia

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity inflammation longevity

Research Overview

Current research on Rehmannia glutinosa (Rehmanniae Radix) is most developed in pharmacology and mechanistic preclinical studies, with emphasis on neurological/cerebrovascular indications and metabolic–immune effects. Across the abstracts, the most frequently studied bioactive classes include iridoid glycosides (notably catalpol; also aucuboside), other glycosides (e.g., phenylpropanoid glycosides such as acteoside), polysaccharides/oligosaccharides, and lipids such as oleic acid. Experimental models commonly used are rodent ischemic stroke paradigms (MCAO/pMCAO) and cell-based injury models (e.g., OGD, oxidative stress in neuronal lines), alongside inflammation-driven kidney injury models (LPS-induced AKI). Reviews also highlight broad reported activities for Rehmannia polysaccharides—antioxidant, hypoglycemic, immunomodulatory, hematopoietic, cardioprotective, and neuroprotective—while noting variability introduced by extraction, purification, and structural heterogeneity.

The strongest evidence in these abstracts supports neuroprotective effects in ischemic stroke models and related mechanisms at the molecular pathway level. Rehmannioside A improved post-ischemic cognitive and neurological outcomes in MCAO rats and increased neuronal cell viability in vitro, with proposed mechanisms involving suppression of ferroptosis and activation of PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling. Catalpol shows convergent benefits in multiple stroke models, including improved behavioral outcomes and evidence for neurovascular unit–relevant effects such as enhanced neural stem cell proliferation/migration/differentiation and increased angiogenesis, potentially mediated through SDF-1α/CXCR4 signaling. Outside the CNS, oleic acid isolated from Rehmannia demonstrated renoprotective effects in LPS-induced AKI models, reducing inflammatory and oxidative stress markers and modulating Ras/MAPK/PPAR-γ signaling, supported by metabolomics changes in multiple pathways.

Key gaps are translational and standardization-related. Despite extensive mechanistic and animal data, the abstracts indicate limited clinical confirmation for many proposed indications; for polysaccharides, clinical use is noted for chronic aplastic anemia and esophageal cancer, but broader effects (e.g., neuroprotection, cardiometabolic benefits) remain underrepresented in clinical practice. Priority needs include rigorous human trials (efficacy, dosing, safety), improved chemical/structural characterization and batch standardization (especially for polysaccharides), comparative studies across preparations (fresh vs. dried root; extracts vs. isolated compounds), and systematic toxicology and drug–herb interaction assessments. Additional research is also needed to clarify which components drive specific therapeutic effects, to validate proposed pathways (e.g., ferroptosis and NVU protection) with causal interventions, and to determine whether preclinical benefits translate to clinically meaningful outcomes in stroke recovery, cognitive impairment, diabetes, and kidney injury.

1. What conditions has Rehmannia been studied for?

  • Ischemic stroke and post-stroke cognitive impairment: Rehmannioside A was studied in a rat MCAO/reperfusion model for cognitive impairment after ischemia, plus SH-SY5Y cell experiments; catalpol was studied in rat pMCAO and OGD models, including neurogenesis/angiogenesis outcomes.

  • Neurovascular unit (NVU) dysfunction in ischemic stroke: Catalpol was investigated for integrated NVU protection in MCAO rats (abstract truncated but clearly framed around NVU protection in stroke).

  • Acute kidney injury (AKI): Oleic acid (OA), described as isolated from Rehmannia glutinosa, was studied in LPS-induced AKI models (mouse and NRK-52e cells).

  • Inflammation/oxidative stress: A purified Rehmannia polysaccharide arabinan (RGP70-2) was studied in vivo and in vitro for anti-inflammatory effects via ROS/NF-κB signaling.

  • Postmenopausal osteoporosis: Catalpol was studied in ovariectomized (OVX) rats and in RANKL-induced osteoclast differentiation models (RAW 264.7 cells).

  • Depression (gut–brain axis): Verbascoside (key active ingredient in a co-decoction including Radix Rehmannia Recens) was studied for depression via gut microbiota–brain axis mechanisms (abstract truncated but indicates this focus).

  • Diabetes/hyperglycemia (traditional use and research focus): A review notes Rehmannia has been used “since ancient times” for diabetes and highlights polysaccharides/oligosaccharides as commonly studied for hypoglycemic activity.

  • Cancer and hematologic conditions (clinical applications mentioned in review): The polysaccharide review states RGPs have been clinically applied in chronic aplastic anemia and esophageal cancer (details not provided in the abstract).

2. Does it work in treating those conditions? Summarize the evidence.

  • Ischemic stroke / cognitive impairment (preclinical evidence)

    • Rehmannioside A: In MCAO/reperfusion rats, intraperitoneal Rehmannioside A (80 mg/kg) improved cognitive impairment and neurological deficits and reduced cerebral infarction; in cell models it increased viability. Mechanistically, it was reported to inhibit ferroptosis and activate PI3K/AKT/Nrf2 and SLC7A11/GPX4 pathways.

    • Catalpol: In pMCAO rats and OGD models, catalpol improved neurological function and promoted neural stem cell proliferation/migration/differentiation and increased vessel density/angiogenesis. Effects were linked to increased SDF-1α/CXCR4 signaling and were inhibited by the CXCR4 inhibitor AMD3100 in vitro.

    • Strength/limits: These are animal/cell studies showing functional and mechanistic signals; the abstracts do not provide human randomized trial evidence for stroke recovery.

  • Acute kidney injury (preclinical evidence)

    • Oleic acid from Rehmannia: In LPS-induced AKI, OA improved kidney function markers (creatinine and urea nitrogen), reduced inflammatory factors and oxidative stress (ROS), and modulated Ras/MAPK/PPAR-γ and apoptotic signaling; metabolomics suggested effects on multiple metabolic pathways. Blocking Ras signaling (salirasib/FTS) reduced OA’s protective effects in cell injury experiments.

    • Strength/limits: Evidence is from mouse and renal cell models; no clinical AKI trials are described in the abstracts.

  • Inflammation/oxidative stress (preclinical evidence)

    • RGP70-2 polysaccharide: Reduced ROS and downregulated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in vivo; in vitro it reduced cytokines, reduced ROS, and inhibited NF-κB p65 nuclear translocation, consistent with a ROS–NF-κB mechanism.

    • Strength/limits: Mechanistic anti-inflammatory signals are shown, but the abstract does not specify disease endpoints in humans.

  • Postmenopausal osteoporosis (preclinical evidence)

    • Catalpol: In OVX rats, catalpol (10–20 mg/kg/day) improved bone mineral density and microstructure and reduced osteoclast density; in vitro it inhibited osteoclast differentiation markers (e.g., NFATc1, Ctsk, Oscar, Trap) and promoted osteoclast apoptosis. Mechanism: Sirt6-dependent ERα deacetylation/stabilization leading to FasL-mediated apoptosis; Sirt6 knockdown eliminated these effects.

    • Strength/limits: Strong mechanistic coherence in animal/cell models; no human fracture/BMD trials are provided in the abstracts.

  • Depression (mechanistic premise; evidence not fully shown in provided text)

    • Verbascoside / LBRD: The abstract states verbascoside (key ingredient) improves brain and gastrointestinal function in patients with depression and aims to clarify gut–brain axis mechanisms, but the results are not included in the excerpt provided.

  • Diabetes, cancer, aplastic anemia (review-level claims)

    • The polysaccharide review describes hypoglycemic, antitumor, immunomodulatory, and hematopoiesis-promoting activities and notes clinical application of RGPs in chronic aplastic anemia and esophageal cancer; however, the abstract does not provide trial designs, effect sizes, or comparative outcomes.

3. What health benefits does it have?

  • Neuroprotection after ischemia: Improved neurological deficits and cognition in rodent stroke models (Rehmannioside A; catalpol), with mechanistic links to ferroptosis inhibition (SLC7A11/GPX4; PI3K/AKT/Nrf2) and to neurogenesis/angiogenesis signaling (SDF-1α/CXCR4).

  • Anti-inflammatory and antioxidant effects: RGP70-2 reduced ROS and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inhibited NF-κB p65 nuclear translocation; OA reduced inflammatory response and oxidative stress in AKI models.

  • Kidney protection in inflammatory injury models: OA improved renal function markers (creatinine, urea nitrogen) and modulated Ras/MAPK/PPAR-γ and apoptosis pathways in LPS-induced AKI models.

  • Bone-protective effects in estrogen-deficiency models: Catalpol improved BMD and bone microstructure and promoted osteoclast apoptosis via the Sirt6–ERα–FasL axis in OVX rats.

  • Potential metabolic and immune benefits (review-level): The polysaccharide review summarizes reported hypoglycemic, immunomodulatory, hematopoiesis-promoting, cardioprotective, and antioxidant activities, but these vary by extraction/purification and are not all supported by clinical outcomes in the abstract.

4. Does it have any downsides or side effects?

The provided abstracts contain limited direct safety reporting, especially for humans. Key limitations and potential downsides based on what is stated:

  • Insufficient toxicity/side-effect characterization: The polysaccharide review explicitly notes the need for more research on “toxicity, side effects and clinical pharmacological effects” of Rehmannia polysaccharides, implying current safety evidence is incomplete.

  • Evidence is largely preclinical: Many findings are from rodent and cell models (stroke, AKI, inflammation, osteoporosis). Translation to human benefit and real-world adverse event rates is uncertain from these abstracts alone.

  • Route/dose differences vs supplements: Rehmannioside A was given by intraperitoneal injection (80 mg/kg) in rats; catalpol was gavaged at 5–20 mg/kg/day in rats. These do not directly map to typical oral supplement dosing in humans, and safety at human-equivalent doses is not established in the abstracts.

  • Potential for pathway-level interactions (theoretical): Several studies involve modulation of major signaling pathways (e.g., PI3K/AKT/Nrf2, Ras/MAPK/PPAR-γ, CXCR4, ERα). While not reported as adverse effects here, such pathway modulation could plausibly interact with medications; the abstracts do not provide interaction data.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are reported in the provided abstracts. None mention genotype-stratified responses, variant-specific efficacy/toxicity, or metabolism differences by common pharmacogenes.

  • Mechanistic clues but not genetic evidence: The abstracts implicate targets/pathways (e.g., Nrf2, GPX4, SLC7A11, CXCR4, Sirt6, ERα, PPAR-γ, Ras/MAPK). These suggest hypotheses that genetic variation in these pathways could influence response, but this is not tested or demonstrated in the abstracts.

  • Practical takeaway: Based on these abstracts alone, there is no evidence to recommend Rehmannia (or its constituents like catalpol/rehmannioside A/verbascoside/polysaccharides) specifically for or against any genetic variants.

References

  1. Rehmannioside A improves cognitive impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling pathway after ischemia.
    Chen Fu, Yifan Wu, Shaojiao Liu, Chaoqin Luo, Yuqiao Lu, Menghan Liu, Lingfeng Wang, Yunling Zhang, Xuemei Liu (2022) - Journal of ethnopharmacology
  2. Extraction, structure and bioactivities of polysaccharides from Rehmannia glutinosa: A review.
    Zhiying Bian, Rui Zhang, Xin Zhang, Jingyi Zhang, Lingchuan Xu, Lihao Zhu, Yan Ma, Yuhong Liu (2023) - Journal of ethnopharmacology
  3. Progress of research into the pharmacological effect and clinical application of the traditional Chinese medicine Rehmanniae Radix.
    Jinhao Jia, Jianfei Chen, Guoli Wang, Minjing Li, Qiusheng Zheng, Defang Li (2023) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling.
    Hong-Jin Wang, Hai-Feng Ran, Yue Yin, Xiao-Gang Xu, Bao-Xiang Jiang, Shi-Qi Yu, Yi-Jin Chen, Hui-Jing Ren, Shan Feng, Ji-Fen Zhang, Yi Chen, Qiang Xue, Xiao-Yu Xu (2022) - Acta pharmacologica Sinica
  5. Oleic acid alleviates LPS-induced acute kidney injury by restraining inflammation and oxidative stress via the Ras/MAPKs/PPAR-γ signaling pathway.
    Beibei Zhang, Mengnan Zeng, Yangyang Wang, Meng Li, Yuanyuan Wu, Ruiqi Xu, Qinqin Zhang, Jufang Jia, Yanjie Huang, Xiaoke Zheng, Weisheng Feng (2022) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Catalpol attenuates ischemic stroke by promoting neurogenesis and angiogenesis via the SDF-1α/CXCR4 pathway.
    Mei-Feng Zhang, Jing-Hui Wang, Si Sun, Yi-Tong Xu, Dong Wan, Shan Feng, Zhen Tian, Hui-Feng Zhu (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  7. Structural characterization and anti-inflammatory effects of an arabinan isolated from Rehmannia glutinosa Libosch.
    Han Zhang, Yimin Yue, Qian Zhang, Lanyuan Liang, Chuanqiu Li, Ying Chen, Wei Li, Mingming Peng, Mengru Yang, Mantong Zhao, Xia Cao, Luyang Zhong, Jieyong Du, Yi Wang, Xi Zhou, Zunpeng Shu (2023) - Carbohydrate polymers
  8. Catalpol attenuates osteoporosis in ovariectomized rats through promoting osteoclast apoptosis via the Sirt6-ERα-FasL axis.
    Shuai Chen, Jie Jin, Ziqing Xu, Huawei Han, Lan Wu, Zhiwei Li (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  9. Molecular and Biochemical Pathways of Catalpol in Alleviating Diabetes Mellitus and Its Complications.
    Subrat Kumar Bhattamisra, Hui Min Koh, Shin Yean Lim, Hira Choudhury, Manisha Pandey (2021) - Biomolecules
  10. Co-decoction of Lilii bulbus and Radix Rehmannia Recens and its key bioactive ingredient verbascoside inhibit neuroinflammation and intestinal permeability associated with chronic stress-induced depression via the gut microbiota-brain axis.
    Qiancheng Mao, Hongxiu Zhang, Zhe Zhang, Yanting Lu, Jin Pan, Dongjing Guo, Liuxuan Huang, Haoquan Tian, Ke Ma (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  11. Oligosaccharides isolated from
    Xiao Li, Rong Gui, Xuefang Wang, Erjuan Ning, Lixian Zhang, Yi Fan, Ling Chen, Liqin Yu, Jie Zhu, Zhining Li, Lei Wei, Wei Wang, Zihong Li, Yue Wei, Xuebing Wang (2023) - Frontiers in nutrition
  12. Immunoenhancement effect of rehmannia glutinosa polysaccharide on lymphocyte proliferation and dendritic cell.
    Yee Huang, Chunmao Jiang, Yuanliang Hu, Xiaojuan Zhao, Cheng Shi, Yun Yu, Cui Liu, Yang Tao, Huarong Pan, Yibo Feng, Jiaguo Liu, Yi Wu, Deyun Wang (2013) - Carbohydrate polymers
  13. The Active Ingredient Catalpol in
    Yang Li, Qiang Chen, Hong-Juan Sun, Jian-Hong Zhang, Xuan Liu (2024) - Diabetes, metabolic syndrome and obesity : targets and therapy
  14. From Plants to Psycho-Neurology: Unravelling the Therapeutic Benefits of Bioactive Compounds in Brain Disorders.
    Clara Grosso, Marlene Santos, M Fátima Barroso (2023) - Antioxidants (Basel, Switzerland)
  15. Changes in Rehmanniae Radix processing and their impact on ovarian hypofunction: potential mechanisms of action.
    Han-Zhi Zhong, Jing Mo, Yan-Xin Li, Mao-Ya Li, Shao-Bin Wei (2024) - Frontiers in pharmacology
  16. Radix Rehmanniae Praeparata promoted zebrafish fin regeneration through aryl hydrocarbon receptor-dependent autophagy.
    Fengyan Chen, Shiming Pu, Li Tian, Huan Zhang, Huixian Zhou, Yijing Yan, Xiaolin Hu, Qiong Wu, Xueping Chen, Shuk Han Cheng, Shisan Xu (2024) - Journal of ethnopharmacology
  17. Effect of structural changes of Rehmannia glutinosa polysaccharide before and after processing on anti-aging activity.
    Ruixiang Shi, Simin Yang, Shuting Zeng, Jiazi Lin, Xiao Wang, Jiamin Yu, Yefang Liang, Jianhua Li, Tong Zhou, Yong'an Deng, Xiaodong Duan, Chengkai Chen, Miao Yu, Guibo Sun, Jun Dong, Zunpeng Shu (2025) - International journal of biological macromolecules
  18. Catalpol fromRehmannia glutinosaTargets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis
    Zhi-Hui Liu, Qing-Yang Xu, Yu Wang, Hong-Xin Gao, Ya-Hong Min (2024)
  19. Rehmannia glutinosa polysaccharides attenuates colitis via reshaping gut microbiota and short-chain fatty acid production.
    Hao Lv, Hongpeng Jia, Wenjie Cai, Rujing Cao, Chenyu Xue, Na Dong (2023) - Journal of the science of food and agriculture
  20. Catalpol ameliorates liver fibrosis via inhibiting aerobic glycolysis by EphA2/FAK/Src signaling pathway.
    Qingxiu Zhang, Tao Ran, Shiliang Li, Lu Han, Shaojie Chen, Guoyuan Lin, Huayue Wu, Huan Wu, Shu Feng, Jiyu Chen, Qian Zhang, Xueke Zhao (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!